Vienna, 5th September 2017 – The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom’s innovation agency, Innovate UK. Themis, the Vienna-based specialist for vaccine development, will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya […]
↧